atorvastatin has been researched along with Cardiomyopathies in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (21.43) | 29.6817 |
| 2010's | 6 (42.86) | 24.3611 |
| 2020's | 5 (35.71) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, ST; Chen, HC; Chen, MC; Chen, YL; Chung, CM; Ho, WC; Kuo, TY; Lee, WC; Lin, MH; Lin, YS; Lip, GYH; Shi, CS | 1 |
| Chou, WC; Gao, G; Jiang, S; Qiu, Z; Tao, L | 1 |
| Anfossi, R; Carrillo, I; Castillo, C; Catalán, M; Clayton, NS; González-Herrera, F; Guzmán-Rivera, D; Kemmerling, U; Maya, JD; Olea-Azar, C; Quilaqueo, ME; Quintero-Pertuz, H; Ridley, AJ; Rivera-Meza, M; Vivar, R | 1 |
| Klinnikova, MG; Koldysheva, EV; Lushnikova, EL; Semenov, DE; Tursunova, NV | 1 |
| Abuawad, Z; Andelova, K; Fulop, M; Kalocayova, B; Kura, B; Sagatova, A; Slezak, J; Sykora, M; Szeiffova Bacova, B | 1 |
| Kachra, R; Lyons, K; Ruzycki, SM | 1 |
| Fang, T; Guo, B; Wang, L; Xue, L | 1 |
| Bagheri, J; Davarpasand, T; Forouzannia, SK; Gorabi, AM; Jalali, A; Lotfi-Tokaldany, M; Shekari, A; Talasaz, AH | 1 |
| Cawley, PJ; Otto, CM | 1 |
| Acar, Z; Ağaç, MT; Demir, S; Demircan, S; Durna, K; Kale, A; Meriç, M; Turgut, M | 1 |
| Cheng, Y; Feng, Y; Gao, J; Huang, B; Lin, G; Wu, Y; Xie, Q; Xu, D | 1 |
| Jena, GB; Kushwaha, S; Ramanjaneyulu, SV; Trivedi, PP; Vikram, A | 1 |
| di Sciascio, G | 1 |
2 review(s) available for atorvastatin and Cardiomyopathies
| Article | Year |
|---|---|
Prevention of calcific aortic valve stenosis-fact or fiction?
Topics: Angiotensin-Converting Enzyme Inhibitors; Aortic Valve Stenosis; Atherosclerosis; Atorvastatin; Calcinosis; Cardiomyopathies; Disease Progression; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Randomized Controlled Trials as Topic; Renin-Angiotensin System | 2009 |
The ARMYDA trials (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) at Campus Bio-Medico University: rationale, results and future horizons.
Topics: Angina Pectoris; Angioplasty; Atorvastatin; Cardiomyopathies; Forecasting; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome | 2007 |
2 trial(s) available for atorvastatin and Cardiomyopathies
| Article | Year |
|---|---|
Comparison of the effect of 80 vs 40 mg atorvastatin in patients with isolated coronary artery bypass graft surgery: A randomized clinical trial.
Topics: Aged; Atorvastatin; Biomarkers; Cardiomyopathies; Coronary Artery Bypass; Coronary Disease; Creatine Kinase, MB Form; Female; Humans; Male; Middle Aged; Postoperative Complications; Single-Blind Method; Time Factors; Troponin T | 2019 |
Effect of 40 mg versus 10 mg of atorvastatin on oxidized low-density lipoprotein, high-sensitivity C-reactive protein, circulating endothelial-derived microparticles, and endothelial progenitor cells in patients with ischemic cardiomyopathy.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cardiomyopathies; Cell-Derived Microparticles; Echocardiography; Endothelial Cells; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Lipoproteins, LDL; Male; Middle Aged; Pyrroles; Stem Cells | 2012 |
10 other study(ies) available for atorvastatin and Cardiomyopathies
| Article | Year |
|---|---|
Statins to prevent pacing-induced cardiomyopathy: Evidence from the bench applied to clinical studies.
Topics: Animals; Atorvastatin; Atrioventricular Block; Cardiac Pacing, Artificial; Cardiomyopathies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Rats; Stroke Volume; Swine; Ventricular Function, Left | 2022 |
Atorvastatin Ameliorates Doxorubicin-Induced Cardiomyopathy by Regulating the Autophagy-Lysosome Pathway and Its Upstream Regulatory Factor Transcription Factor EB.
Topics: Animals; Atorvastatin; Autophagy; Cardiomyopathies; Doxorubicin; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lysosomes; Mice | 2022 |
Statins change the cytokine profile in
Topics: Animals; Atorvastatin; Cardiomyopathies; Chagas Disease; Cytokines; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Macrophages; Mice; NF-kappa B; rho-Associated Kinases; Trypanosoma cruzi; U937 Cells | 2022 |
Features of Myocardial Remodeling and Changes in the Blood Lipid Spectrum in Experimental Doxorubicin-Induced Cardiomyopathy and Atorvastatin Administration.
Topics: Animals; Antibiotics, Antineoplastic; Anticholesteremic Agents; Atorvastatin; Atrial Remodeling; Body Weight; Cardiomyopathies; Cholesterol; Doxorubicin; Dyslipidemias; Female; Lipoproteins, VLDL; Myocytes, Cardiac; Organ Size; Rats; Rats, Wistar; Triglycerides | 2020 |
The effect of selected drugs on the mitigation of myocardial injury caused by gamma radiation.
Topics: Animals; Atorvastatin; Cardiomyopathies; Free Radicals; Gamma Rays; Heart; Male; Malondialdehyde; Myocardium; Oxidative Stress; Radiation Injuries, Experimental; Rats; Tadalafil; Treatment Outcome; Tumor Necrosis Factor-alpha | 2021 |
A 71-year-old woman with an asymptomatic postoperative troponin elevation.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Atorvastatin; Biomarkers; Cardiomyopathies; Endometrial Neoplasms; Female; Guidelines as Topic; Gynecologic Surgical Procedures; Humans; Perindopril; Postoperative Care; Postoperative Complications; Troponin T | 2019 |
Atorvastatin Prevents Myocardial Fibrosis in Spontaneous Hypertension via Interleukin-6 (IL-6)/Signal Transducer and Activator of Transcription 3 (STAT3)/Endothelin-1 (ET-1) Pathway.
Topics: Animals; Atorvastatin; Blood Pressure; Cardiomyopathies; Disease Models, Animal; Endomyocardial Fibrosis; Endothelin-1; Fibrosis; Hypertension; Interleukin-6; Male; Myocardium; Phosphorylation; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Signal Transduction; STAT3 Transcription Factor | 2019 |
Adolescent type 1 Diabetes Cardio-renal Intervention Trial (AdDIT).
Topics: Adolescent; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Area Under Curve; Atorvastatin; Biomarkers; Cardiomyopathies; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Multicenter Studies as Topic; Puberty; Pyrroles; Quinapril; Randomized Controlled Trials as Topic; Research Design; Risk; Tetrahydroisoquinolines | 2009 |
Efficiency of atorvastatin in the protection of anthracycline-induced cardiomyopathy.
Topics: Adult; Aged; Anthracyclines; Atorvastatin; Cardiomyopathies; Cardiotonic Agents; Female; Follow-Up Studies; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Treatment Outcome | 2011 |
Protective role of atorvastatin against doxorubicin-induced cardiotoxicity and testicular toxicity in mice.
Topics: Animals; Antioxidants; Atorvastatin; Cardiomyopathies; Comet Assay; DNA Fragmentation; Doxorubicin; Glutathione; Heart; Heptanoic Acids; Lipid Peroxidation; Male; Malondialdehyde; Mice; Micronucleus Tests; Oxidative Stress; Pyrroles; Testicular Diseases; Testis | 2013 |